ABSTRACT
Therapeutic chaperone effect of a valienamine derivative N-octyl 4-epi-ß-valienamine (NOEV) was studied in G(M1)-gangliosidosis model mice. Phamacokinetic analysis revealed rapid intestinal absorption and renal excretion after oral administration. Intracellular accumulation was not observed after continuous treatment. NOEV was delivered to the central nervous system through the blood-brain barrier to induce high expression of the apparently deficient ß-galactosidase activity. NOEV treatment starting at the early stage of disease resulted in remarkable arrest of neurological progression within a few months. Survival time was significantly prolonged. This result suggests that NOEV chaperone therapy will be clinically effective for prevention of neuronal damage if started early in life hopefully also in human patients with G(M1)-gangliosidosis.
Subject(s)
Gangliosidosis, GM1/therapy , Hexosamines/administration & dosage , Molecular Chaperones/administration & dosage , beta-Galactosidase/genetics , beta-Glucosidase/genetics , Animals , Blood-Brain Barrier , Central Nervous System/enzymology , Central Nervous System/pathology , Disease Models, Animal , Gangliosidosis, GM1/enzymology , Gangliosidosis, GM1/pathology , Gene Expression Regulation/drug effects , Hexosamines/pharmacokinetics , Humans , Intestinal Mucosa/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Molecular Chaperones/pharmacokinetics , UrinalysisABSTRACT
Certain low-molecular-weight substrate analogs act both as in vitro competitive inhibitors of lysosomal hydrolases and as intracellular enhancers (chemical chaperones) by stabilization of mutant proteins. In this study, we performed oral administration of a chaperone compound N-octyl-4-epi-beta-valienamine to G(M1)-gangliosidosis model mice expressing R201C mutant human beta-galactosidase. A newly developed neurological scoring system was used for clinical assessment. N-Octyl-4-epi-beta-valienamine was delivered rapidly to the brain, increased beta-galactosidase activity, decreased ganglioside G(M1), and prevented neurological deterioration within a few months. No adverse effect was observed during this experiment. N-Octyl-4-epi-beta-valienamine will be useful for chemical chaperone therapy of human G(M1)-gangliosidosis.
Subject(s)
Gangliosidosis, GM1/drug therapy , Gangliosidosis, GM1/physiopathology , Hexosamines/therapeutic use , Molecular Chaperones/therapeutic use , Nervous System/drug effects , Nervous System/physiopathology , Animals , Brain/metabolism , Gangliosidosis, GM1/metabolism , Hexosamines/pharmacokinetics , Humans , Immunohistochemistry , Kidney/metabolism , Liver/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic , Molecular Chaperones/pharmacokinetics , Mutation , Nervous System/metabolism , Osmolar Concentration , Tissue Distribution , beta-Galactosidase/deficiency , beta-Galactosidase/genetics , beta-Galactosidase/metabolismABSTRACT
We performed screening of beta-galactosidase-deficient fibroblasts for possible chemical chaperone therapy using N-octyl-4-epi-beta-valienamine (NOEV) in patients with GM1-gangliosidosis and Morquio B disease (beta-galactosidosis). Fibroblasts were cultured with NOEV for 4 days and beta-galactosidase activity was measured. Mutation analysis was performed simultaneously. Two separate criteria were set for evaluation of the chaperone effect: a relative increase of enzyme activity (more than 3-fold), and an increase up to more than 10% normal enzyme activity. Among the 50 fibroblast strains tested, more than 3-fold increase was achieved in 17 cell strains (34%), and more than 10% normal activity in 10 (20%). Both criteria were satisfied in 6 (12%), and either of them in 21 (42%). Juvenile GM1-gangliosidosis was most responsive, and then infantile GM1-gangliosidosis. This enhancement was mutation-specific. We estimate that the NOEV chaperone therapy will be effective in 20-40% of the patients, mainly in juvenile and infantile GM1-gangliosidosis patients. A molecular design may produce mutation-specific chaperone compounds for the other disease phenotypes. This cellular screening will be useful for identification of human patients with beta-galactosidase deficiency for chaperone therapy to be started in the near future.
